Annexon, Inc. (NASDAQ:ANNX) Given Consensus Recommendation of “Buy” by Brokerages

Annexon, Inc. (NASDAQ:ANNX) has earned an average recommendation of “Buy” from the six analysts that are covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $15.80.

A number of research firms have recently commented on ANNX. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Needham & Company LLC restated a “buy” rating and issued a $16.00 price target on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th.

Annexon Trading Up 2.0 %

Shares of ANNX opened at $3.07 on Friday. Annexon has a twelve month low of $2.87 and a twelve month high of $8.40. The firm has a market capitalization of $327.23 million, a P/E ratio of -2.92 and a beta of 1.07. The stock’s fifty day simple moving average is $4.45 and its 200 day simple moving average is $5.66.

Hedge Funds Weigh In On Annexon

Several hedge funds and other institutional investors have recently bought and sold shares of ANNX. SG Americas Securities LLC raised its stake in shares of Annexon by 117.8% during the third quarter. SG Americas Securities LLC now owns 32,763 shares of the company’s stock valued at $194,000 after purchasing an additional 17,723 shares during the period. Creative Planning grew its holdings in Annexon by 29.5% during the 3rd quarter. Creative Planning now owns 34,779 shares of the company’s stock valued at $206,000 after purchasing an additional 7,914 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in Annexon by 34.7% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 259,404 shares of the company’s stock worth $1,536,000 after buying an additional 66,792 shares during the period. GSA Capital Partners LLP lifted its holdings in Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after buying an additional 3,355 shares in the last quarter. Finally, Mutual of America Capital Management LLC boosted its position in Annexon by 3.1% in the 3rd quarter. Mutual of America Capital Management LLC now owns 659,254 shares of the company’s stock valued at $3,903,000 after buying an additional 19,681 shares during the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.